drugset / Trial / NCT05325775
Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this clinical research study, subjects will be given the study drug, ACER-801 (osanetant) or placebo (looks like the study drug but contains no active ingredients). The study drug works on a receptor in the brain and the intended purpose is for the study treatment of moderate to severe Vasomotor Symptoms (VMS) also referred to as hot flashes or flushes associated with menopause. Hot flashes are a change in your temperature that occurs due to changes in your hormones.
Timeline
- Start
- 2022-03-30
- Primary completion
- 2023-03-04
- Completion
- 2023-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACER-801 | Unknown | 50 mg | — |
| Subject | ACER-801 | Unknown | 100 mg | — |
| Subject | ACER-801 | Unknown | 200 mg | — |
Indications
No indication recorded.